Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND3 | P30281 | 3/20 | 0.49 |
| ▸ | CDK2 | P24941 | 3/20 | 0.49 |
| ▸ | CCNK | O75909 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 5/20 | 0.47 |
| ▸ | CDK4 | P11802 | 4/20 | 0.46 |
| ▸ | CCND1 | P24385 | 4/20 | 0.46 |
| ▸ | CCND2 | P30279 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 3/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6074236 | 0.91 | CDK2 (0.53) | CCND3CDK2CCNKCCNA2CDK9 | |
| SCHEMBL6074119 | 0.90 | CDK2 (0.48) | CCND3CDK2CCNKCCNA2CDK9 | |
| SCHEMBL6073911 | 0.86 | CDK2 (0.54) | CCND3CDK2CCNKCCNA2CDK9 | |
| SCHEMBL6073563 | 0.85 | CDK4 (0.50) | CCND3CDK2CCNA2CDK9CDK6 | |
| SCHEMBL6073647 | 0.85 | CDK2 (0.56) | CCND3CDK2CCNKCCNA2CDK9 | |
| SCHEMBL6073490 | 0.85 | CCND3 (0.50) | CCND3CDK2CCNKCCNA2CDK9 | |
| SCHEMBL7503346 | 0.85 | CCND3 (0.47) | CCND3CDK2CCNKCCNA2CDK9 | |
| SCHEMBL6074138 | 0.83 | CDK2 (0.58) | CCND3CDK2CCNKCCNA2CDK9 | |
| SCHEMBL6074107 | 0.83 | CDK2 (0.51) | CCND3CDK2CCNKCCNA2CDK9 | |
| SCHEMBL6073855 | 0.82 | CDK4 (0.54) | CCND3CDK2CCNKCCNA2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053070-B2 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | BOOTH RICHARD JOHN (US) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | CDK9, CDK19, CDK3 | CCND3 98/4885CDK2 5/4885CCNK 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.